<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511416</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT04511416</nct_id>
  </id_info>
  <brief_title>Preventing Cognitive Decline With Metformin</brief_title>
  <acronym>MetMemory</acronym>
  <official_title>Preventing Cognitive Decline With Metformin:: The MetMemory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Garvan Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Garvan Institute of Medical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised control study of metformin in people with mild cognitive impairment and without&#xD;
      diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised placebo-control study of metformin in people with mild cognitive impairment and&#xD;
      without diabetes mellitus to determine effects on cognitive decline, neuroimaging and&#xD;
      biomarkers over 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomised placebo controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in memory Z-score</measure>
    <time_frame>3 years</time_frame>
    <description>memory domain Z-score, derived from the following neuropsychological tests: i. Rey Auditory Verbal Learning Test (RAVLT); ii. Total Learning and Delayed recall; iii. the Logical Memory Story A- Immediate Recall; and iv. Delayed Recall tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in executive function Z-score</measure>
    <time_frame>3 years</time_frame>
    <description>executive function domain Z-score, derived from the following neuropsychological tests: i. Alphabet test; ii. D-KEFS Stroop; iii. Trail Making Test Part B; iv. Weschler Adult Intelligence Scale-IV (WAIS-IV) Digit Span Backward test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in processing speed domain Z-score</measure>
    <time_frame>3 years</time_frame>
    <description>processing speed domain measured by the i. WAIS-IV Coding; and ii. Trail Making Test part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in language performance domain Z-score</measure>
    <time_frame>3 years</time_frame>
    <description>language performance domain measured by the Category Fluency (Animals) neuropsychological test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in attention performance domain Z-score</measure>
    <time_frame>3 years</time_frame>
    <description>attention performance domain Z-score, measured by the WAIS-IV Digit Span Forward neuropsychological test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Cogstate brief battery performance Z-score</measure>
    <time_frame>3 years</time_frame>
    <description>computerised cognition testing using the on-line test, the Cogstate brief battery (CBB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in total brain volume (cubic millimetres)</measure>
    <time_frame>3 years</time_frame>
    <description>total grey and white matter volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in hippocampal volume (cubic millimetres)</measure>
    <time_frame>3 years</time_frame>
    <description>volume of the right and left hippocampal regions of the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in parahippocampal volume (cubic millimetres)</measure>
    <time_frame>3 years</time_frame>
    <description>volume of the right and left parahippocampal regions of the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in brain white matter hyperintensity number</measure>
    <time_frame>3 years</time_frame>
    <description>the number of white matter hyperintensities visualised in bain imaging by magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in cerebral blood flow (mL / 100 g / min)</measure>
    <time_frame>3 years</time_frame>
    <description>Cerebral blood flow will be measured using arterial spin labelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in cerebral amyloid tracer standardized uptake value ratio (SUVR)</measure>
    <time_frame>3 years</time_frame>
    <description>standardized uptake value ratio of amyloid tracer using positron emission tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in cognitive performance Z-score using the NIH tool box</measure>
    <time_frame>3 years</time_frame>
    <description>The NIH Toolbox currently contains the following cognitive tests: Flanker, Pattern Comparison, Picture Sequence Memory and Dimensional Change Card Sort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in BOLD (blood-oxygen-level-dependent) time-series signals measured by functional magnetic resonance imaging</measure>
    <time_frame>3 years</time_frame>
    <description>change blood oxygen-level-dependent time-series signals, measured by functional MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in biomarkers, including fasting glucose (mmol/L) and insulin (mIU/L), insulin resistance (HOMA-IR index)</measure>
    <time_frame>3 years</time_frame>
    <description>fasting glucose (mmol/L) and insulin (mIU/L), insulin resistance (HOMA-IR index)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR, 500-2000mg nocte</intervention_name>
    <description>anti diabetic medication</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  overweight or obese (body mass index &gt;25.0 kg/m2, waist: women&gt;80 cm, men&gt;94cm;&#xD;
&#xD;
          -  Mild cognitive impairment (Mild Neurocognitive Disorder), based on DSM-5 criteria;&#xD;
&#xD;
          -  Fasting blood glucose &lt;7.0 mmol/L and HbA1c &lt;6.5%;&#xD;
&#xD;
          -  Able to undertake neurocognitive testing in English.&#xD;
&#xD;
          -  Not participating in another trial of drugs or lifestyle modification to reduce&#xD;
             cognitive decline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life-threatening illnesses to preclude participation in a 3-year study;&#xD;
&#xD;
          -  Contraindications to the use of metformin (severe heart failure or eGFR &lt;40).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katherine Samaras, MD, PhD</last_name>
    <phone>61292958312</phone>
    <email>k.samaras@garvan.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Professor Katherine Samaras</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Katherine Samaras, MBBS FRACP PhD</last_name>
      <email>k.samaras@garvan.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Garvan Institute to Medical Research</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive decline</keyword>
  <keyword>dementia</keyword>
  <keyword>cerebrovascular disease</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>neurodegeneration</keyword>
  <keyword>inflammation</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

